Advanced Viral Research Corp. Shares Progress of AVR118 Phase II Cancer Cachexia Study at McGill University

April 1, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

YONKERS, NY--(Marketwire - April 01, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR) announced today that enrollment for its Phase II efficacy study for AVR118 in cancer cachexia is progressing in line with expectations.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2